RT Journal Article
SR Electronic
T1 Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
JF Cancer Biology and Medicine
JO Cancer Biol Med
FD China Anti-Cancer Association
SP 79
OP 86
DO 10.7497/j.issn.2095-3941.2015.0029
VO 12
IS 2
A1 Karachaliou, Niki
A1 Cao, Maria Gonzalez
A1 Teixidó, Cristina
A1 Viteri, Santiago
A1 Morales-Espinosa, Daniela
A1 Santarpia, Mariacarmela
A1 Rosell, Rafael
YR 2015
UL http://www.cancerbiomed.org/content/12/2/79.abstract
AB Survival rates for metastatic lung cancer, including non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), are poor with 5-year survivals of less than 5%. The immune system has an intricate and complex relationship with tumorigenesis; a groundswell of research on the immune system is leading to greater understanding of how cancer progresses and presenting new ways to halt disease progress. Due to the extraordinary power of the immune system—with its capacity for memory, exquisite specificity and central and universal role in human biology—immunotherapy has the potential to achieve complete, long-lasting remissions and cures, with few side effects for any cancer patient, regardless of cancer type. As a result, a range of cancer therapies are under development that work by turning our own immune cells against tumors. However deeper understanding of the complexity of immunomodulation by tumors is key to the development of effective immunotherapies, especially in lung cancer.